|Specificity:||The antibody MEM-83 reacts with CD11a (alpha subunit of human LFA-1), a 170-180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils.
HLDA IV; WS Code N 211
|Immunogen:||Human peripheral blood lymphocytes|
The antibody MEM-83 directly induces the binding of T cells to purified ICAM-1. Using an in vitro-translated CDlla cDNA deletion series, the MEM-83 activation epitope was mapped to the "I" domain of the LFA-1 alpha subunit. The studies have therefore identified a novel LFA-1 activation epitope mapping to the I domain of LFA-1, which could play a role in the regulation of LFA-1 binding to ICAM-1.
Recommended dilution:1 μg/ml
|Purity:||> 95% (by SDS-PAGE)|
|Purification:||Purified by protein-A affinity chromatography|
|Storage Buffer:||Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4|
|Storage / Stability:||Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.|
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD11a (LFA-1 alpha) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.|
*Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI: Leukocyte function-associated antigen 1-mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule-1. J Biol Chem. 2005 Aug 5;280(31):28290-8.
*Giblin PA, Lemieux RM: LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. Curr Pharm Des. 2006;12(22):2771-95.
*Kellersch B, Kolanus W: Membrane-proximal signaling events in beta-2 integrin activation. Results Probl Cell Differ. 2006;43:245-57.
*Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function-associated antigen-1 in the regulation of lymphocytic cholinergic activity. Life Sci. 2007 May 30;80(24-25):2320-4.
*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
*Landis RC, Bennett RI, Hogg N: A novel LFA-1 activation epitope maps to the I domain. J Cell Biol. 1993 Mar;120(6):1519-27.
*Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. J Cell Biol. 1994 Jul;126(2):529-37.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic